Cargando…

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

BACKGROUND: Effects of roflumilast on lung function, symptoms, acute exacerbation and adverse events in patients with chronic obstructive pulmonary disease (COPD) are controversial. We aimed to further clarify the efficacy and safety of roflumilast in treatment of moderate-to-severe COPD. METHODS: F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jian, Wang, Ke, Liu, Dan, Liang, Bin-Miao, Liu, Chun-Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756424/ https://www.ncbi.nlm.nih.gov/pubmed/26887407 http://dx.doi.org/10.1186/s12931-016-0330-y

Ejemplares similares

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Roflumilast, a type of phosphodiesterase 4 inhibitor, can reduce intestinal injury caused by sepsis
por: Zhang, Zhongyuan, et al.
Publicado: (2021)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
por: Rieder, Florian, et al.
Publicado: (2013)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation‐induced deficits in spatial pattern separation
por: Heckman, Pim R. A., et al.
Publicado: (2020)

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials
por: Rennard, Stephen I, et al.
Publicado: (2014)

Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury
por: Xu, Xingkai, et al.
Publicado: (2020)

Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia
por: Livingston, Nicholas R, et al.
Publicado: (2021)

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
por: Kim, Kyung Hoon, et al.
Publicado: (2017)

Characterization of Resveratrol, Oxyresveratrol, Piceatannol and Roflumilast as Modulators of Phosphodiesterase Activity. Study of Yeast Lifespan
por: Matencio, Adrián, et al.
Publicado: (2020)

Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca(2+)-channel
por: Imam, Faisal, et al.
Publicado: (2020)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
por: Alispahic, Imane Achir, et al.
Publicado: (2020)

The Phosphodiesterase 4 Inhibitor Roflumilast Protects against Cigarette Smoke Extract-Induced Mitophagy-Dependent Cell Death in Epithelial Cells
por: Kyung, Sun Young, et al.
Publicado: (2018)

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients
por: Gilleen, James, et al.
Publicado: (2018)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
por: Gyldenløve, Mette, et al.
Publicado: (2023)

Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review
por: Kazmi, Imran, et al.
Publicado: (2022)

Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Naseem, Sumbal, et al.
Publicado: (2022)

Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
por: Goonathilake, Mastiyage R, et al.
Publicado: (2022)

The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice
por: Wang, Hao, et al.
Publicado: (2020)

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Hwang, Hyunjung, et al.
Publicado: (2015)

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
por: Fu, Alex Z, et al.
Publicado: (2015)

Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
por: Shah, Chirag A.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Facius, Axel, et al.
Publicado: (2018)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Carotid artery intima media thickness can predict the response to phosphodiesterase 5 inhibitors in patients with moderate erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization
por: Momin, Mohammad A. M., et al.
Publicado: (2021)

Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast
por: Varney, Veronica Ann, et al.
Publicado: (2020)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Body mass index, airflow obstruction, dyspnea, and exercise index is not modified after 6 months therapy with roflumilast in a cohort of patients with chronic obstructive pulmonary disease
por: Dragonieri, Silvano, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qthmg0732uakci4krianq1tqa9